MedTrace Logo

Arterial Pressure and Stress-Dose Steroids in Cardiac Arrest.

NCT02785224 · Status: WITHDRAWN · Type: OBSERVATIONAL

Last updated 2025-03-30

No results posted yet for this study

Summary

Early stress-dose steroids are of uncertain efficacy in cardiac arrest. The current authors plan to conduct a pertinent mediation analysis using prospectively collected data from 2 prior randomized clinical trials of in-hospital cardiac arrest. These trials reported positive results on the vasopressin-steroids-epinephrine (VSE) combination. The current analysis is aimed at identifying mediators of the benefit associated with VSE, potentially attributable to its stress-dose steroid subcomponent. Tested mediators will include arterial pressure in the early postresuscitation period (primary), and arterial blood lactate in the early postresuscitation period and renal failure free days (secondary).

Conditions

  • Cardiac Arrest

Interventions

DRUG

Vasopressin Steroids Epinephrine

Vasopressin Steroids Epinephrine: Vasopressin (up to 5 doses of 20 IU) and methylprednisolone (single dose - 40 mg) in addition to epinephrine during cardiopulmonary resuscitation, and stress dose hydrocortisone (300 mg/day for 7 days maximum followed by gradual taper) for postresuscitation shock.

Sponsors & Collaborators

  • University of Thessaly

    collaborator OTHER

  • University of Athens

    lead OTHER

Principal Investigators

  • Spyros D. Mentzelopoulos, MD, PhD · University of Athens

  • Spyros G. Zakynthinos, MD, PhD · University of Athens

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-12-31
Primary Completion
2026-12-31
Completion
2026-12-31

Countries

  • Greece

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02785224 on ClinicalTrials.gov